About: Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis
Creator	Chan, John Fader, Amanda Huh, Warner Kesterson, Joshua Pothuri, Bhavana Armstrong, Deborah Liu, Joyce Moore, Kathleen Naumann, R Secord, Angeles Westin, Shannon
topic	covid:b98246a42a4721a124b80838682e97f390a07043#this
Source	Elsevier; Medline; PMC
abstract	Abstract Objectives The COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patients with cancer may have factors which place them at high risk for COVID 19 morbidity or mortality. Highly immunosuppressive chemotherapy regimens and possible exposure to COVID-19 during treatment may put patients at additional risk. The Society of Gynecologic Oncology convened an expert panel to address recommendations for best practices during this crisis to minimize risk to patients from deviations in cancer care and from COVID-19 morbidity. Methods An expert panel convened to develop initial consensus guidelines regarding anti-neoplastic therapy during the COVID-19 pandemic with respect to gynecologic cancer care and clinical trials. Results COVID-19 poses special risks to patients who are older, have medical co-morbidities, and cancer. In addition, this pandemic will likely strain resources, making delivery of cancer care or conduct of clinical trials unpredictable. Recommendations are to limit visits and contact with health care facilities by using telemedicine when appropriate, and choosing regimens which require less frequent visits and which are less immunosuppressive. Deviations will occur in clinical trials as a result of limited resources, and it is important to understand regulatory obligations to trial sponsors as well as to the IRB to ensure that clinical trial and patient safety oversight are maintained. Conclusions The ongoing crisis will strain resources needed to deliver cancer care. When alterations to the delivery of care are mandated, efforts should be taken to minimize risks and maximize safety while approximating standard practice.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1016/j.ygyno.2020.04.694
bibo:pmid	32386911
has license	els-covid
sha1sum (hex)	b98246a42a4721a124b80838682e97f390a07043
schema:url	https://doi.org/10.1016/j.ygyno.2020.04.694
resource representing a document's title	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis
has PubMed Central identifier	PMC7177100
has PubMed identifier	32386911
schema:publication	Gynecol Oncol
resource representing a document's body	covid:b98246a42a4721a124b80838682e97f390a07043#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/b98246a42a4721a124b80838682e97f390a07043
is schema:about of	named entity 'immunosuppressive' named entity 'additional' named entity 'Patients' named entity 'CONSENSUS' named entity 'COVID-19 PANDEMIC' named entity 'PRE' named entity 'GYNECOLOGIC CANCER' named entity 'IMPACTED' named entity 'BEST PRACTICES' named entity 'PROOF' named entity 'DURING TREATMENT' named entity 'OBJECTIVES' covid:arg/b98246a42a4721a124b80838682e97f390a07043 named entity 'Methods' named entity 'gynecologic cancer' named entity 'expert' named entity 'cancer care' named entity 'develop' named entity 'Clinical Trial' named entity 'clinical trial' named entity 'COVID-19 pandemic' named entity 'COVID-19 pandemic' named entity 'morbidity' named entity 'cancer Therapy' named entity 'dactinomycin' named entity 'metastatic' named entity 'EMA' named entity 'ovarian cancer' named entity 'methotrexate' named entity 'Pazopanib' named entity 'Chemotherapy' named entity '21 days' named entity 'clinical trials' named entity 'endometrial' named entity 'ER positive' named entity 'follow-up' named entity 'clinical trials' named entity 'pulmonary toxicity' named entity 'endometrial cancer' named entity 'hormonal therapy' named entity 'toxicity' named entity 'lymph node' named entity 'everolimus' named entity 'megestrol acetate' named entity 'Aromatase inhibitors' named entity 'asthma' named entity 'viral infection' named entity 'doxorubicin' named entity 'immature teratomas' named entity 'chemotherapy' named entity 'megestrol acetate' named entity 'anti-angiogenic' named entity 'ICU' named entity 'Radiation therapy' named entity 'COVID-19 infection' named entity 'docetaxel' named entity 'anti-cancer' named entity 'docetaxel' named entity 'Neoadjuvant chemotherapy' named entity 'composite endpoint' named entity 'cervical cancer' named entity 'toxicity' named entity 'Hysterectomy' named entity 'doxorubicin' named entity 'general population' named entity 'respiratory failure' named entity 'serous ovarian cancer' named entity 'tamoxifen' named entity 'monotherapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software